10-K: Relay Therapeutics Reports 2024 Results, Highlights RLY-2608 Progress and Pipeline Expansion

Relay Therapeutics' 10-K filing summarizes the company's financial results for 2024, highlights the clinical progress of RLY-2608, and outlines its strategy for pipeline expansion in precision oncology and genetic diseases.

Summary

• Relay Therapeutics, a clinical-stage precision medicine company, filed its 10-K report for the year ended December 31, 2024.
• The company is focused on transforming drug discovery using computational and experimental technologies.
• Relay's lead product candidate, RLY-2608, is undergoing clinical trials, with interim data suggesting differentiated efficacy signals and an encouraging safety profile.
• In September 2024, interim clinical data for RLY-2608 showed a median progression-free survival (PFS) of 9.2 months and an objective response rate (ORR) of 33% in patients without PTEN or AKT co-mutation.
• Updated data in December 2024 showed a median PFS of 9.2 months for all patients and 11.4 months for second-line patients, with a 67% clinical benefit rate.
• The company is planning to initiate a Phase 3 registrational study (ReDiscover-2) to evaluate RLY-2608 plus fulvestrant in advanced breast cancer patients.
• Relay is expanding its pipeline with new programs in vascular malformations, Fabry disease, and an NRAS-selective inhibitor (RLY-8161).
• In December 2024, Relay entered into an exclusive global licensing agreement with Elevar Therapeutics for lirafugratinib (RLY-4008).
• The company reported net losses of $337.7 million for 2024, $342.0 million for 2023, and $290.5 million for 2022.
• As of December 31, 2024, Relay had cash, cash equivalents, and investments of $781.3 million, expected to fund operations into the second half of 2027.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's positive progress in clinical trials and pipeline expansion, the company is still operating at a loss and requires additional funding. The sentiment is cautiously optimistic.

Positives

• RLY-2608 shows promising interim efficacy and safety data in clinical trials.
• Pipeline is expanding with new programs in precision oncology and genetic diseases.
• Strategic partnership with Elevar Therapeutics for lirafugratinib.
• Strong cash position of $781.3 million provides runway into the second half of 2027.
• The company completed a public offering in September 2024, raising $218.2 million.

Negatives

• The company has a limited operating history and has incurred net losses in each year since its inception.
• The company has no products approved for commercial sale and has not generated any revenue from product sales.
• The company expects to continue to incur significant expenses and operating losses for the foreseeable future.

Risks

• Clinical trial outcomes are uncertain, and positive early results may not predict later success.
• Regulatory approvals are not guaranteed and may be delayed or limited.
• The company faces substantial competition in the biopharmaceutical industry.
• Reliance on third parties for clinical trials and manufacturing poses risks.
• The company will need to raise substantial additional funding, and failure to do so could impact development programs.
• The company's ability to protect proprietary technology and obtain patent protection is critical but uncertain.
• Healthcare legislative reforms and changes in reimbursement policies could affect profitability.
• The company is subject to ongoing regulatory obligations and continued regulatory review, and its product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval, which may result in significant additional expense.

Future Outlook

Relay Therapeutics expects its existing cash, cash equivalents, and investments to fund its operating expenses and capital expenditure requirements into the second half of 2027. The company plans to continue advancing its pipeline and may seek additional financing in the future.

Industry Context

Relay Therapeutics operates in the competitive biopharmaceutical industry, focusing on precision medicine targets in oncology and genetic diseases. The company faces competition from major pharmaceutical and biotechnology companies, academic institutions, and research organizations. The success of Relay's product candidates will depend on their efficacy, safety, convenience, price, and reimbursement from third-party payors.

Comparison to Industry Standards

• The document mentions several competing drugs and companies in the PI3K and FGFR2 inhibitor space, including Piqray (Novartis), Truqap (AstraZeneca), Itovebi (Roche/Genentech), Celcuity Inc, Totus Medicines, Scorpion Therapeutics, and OnKure.
• For vascular malformations, the document notes competition with Vijoice (Novartis).
• In Fabry disease, Relay expects to compete with Galafold (Amicus Therapeutics), Fabrazyme (Sanofi), Replagal (Takeda), and Elfabrio (Protalix Biotherapeutics).
• For NRAS-selective inhibitors, the document mentions Braftovi (encorafenib) and Mektovi (binimetinib) marketed by Pfizer, and Revolution Medicines RMC-6236.

Legal Proceedings

• On December 18, 2024, a derivative complaint was filed in the Court of Chancery of the State of Delaware, alleging that certain of our directors and officers awarded the members of our Board of Directors excessive compensation.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful drug development and commercialization, but also risk of dilution from future equity offerings.
• Employees: Continued employment and potential for career growth, but also risk of job losses if the company faces financial difficulties.
• Patients: Potential for new and improved treatments for cancer and genetic diseases.
• Collaborators: Opportunities for partnerships and revenue sharing, but also risk of disagreements and termination of agreements.

Next Steps

• Initiate Phase 3 registrational study (ReDiscover-2) for RLY-2608.
• Advance RLY-2608 in vascular malformations.
• Continue development of programs for Fabry disease and NRAS-selective inhibitor.
• Seek regulatory approval for product candidates.
• Establish commercial manufacturing capabilities.
• Continue to monitor and respond to the ongoing litigation.

Key Dates